Jump to content

Brexpiprazole: Difference between revisions

From Pharmacopedia
[checked revision][pending revision]
Pharmacopedia: add <pharmaInteractions/>
Assign pharmacological categories from List_of_CNS-active_medicines
Line 31: Line 31:
}}
}}


[[Category:Antipsychotics / Neuroleptics]]
[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
[[Category:Neuroleptics]]
[[Category:Neuroleptics]]

Revision as of 15:06, 14 May 2026

Antipsychotic, Neuroleptic
Brexpiprazole
Rexulti

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions1 edge
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 poor metabolizer monitor DPWG 40 / 100
DPWG guideline: The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the normal dose of brexpiprazole for poor metabolizers of CYP2D6.

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Antipsychotic, Neuroleptic
Common uses
Pharmacy
Pharmacology
Purported mechanism
D2/5-HT1A partial agonist; 5-HT2A/alpha antagonist